[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614457":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":18,"studyPopulation":19,"armGroups":20,"interventions":25,"overallOfficials":30,"centralContacts":35,"locations":11,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":11,"eligibilityCriteria":50,"healthyVolunteers":47,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":11,"briefSummary":10,"conditions":58,"keywords":11,"overallStatus":60,"whyStopped":11,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":11},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"To evaluate the long-term safety of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years",null,"52 weeks after core-shell injection",[14],{"measure":15,"description":11,"timeFrame":12},"Assess the metabolic activity of related enzymes in patients with primary PD over 5 years following RGL-193 capsid injection.",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":17,"maskingInfo":11},"OTHER","An open-label, observational, long-term follow-up study evaluating the safety and efficacy of RGL-193 capsid injection in patients with primary Parkinson's disease over 5 years","Patients with mid-to-late stage Parkinson's disease",[21],{"label":22,"type":11,"description":11,"interventionNames":23},"Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treat",[24],"Other: Observational",[26],{"type":17,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"Observational","Long-term observational",[22],[31],{"name":32,"affiliation":33,"role":34},"Chaoshi Niu","The First Affiliated Hospital of University of Science and Technology of China","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":11,"email":39},"CONTACT","+86 13855186208","niuchaoshi@163.com",{"name":41,"role":37,"phone":42,"phoneExt":11,"email":43},"Chi Xiong","+86 18709857411","xiongchi@ustc.edu.cn",{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100614457",false,"NCT07279844","An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection in Patients With Primary Parkinson's Disease","Inclusion Criteria:\n\n1. Subjects who have previously participated in RGL-193-related studies and have received RGL-193 treatment；\n2. Those who voluntarily participate in this trial and sign a written informed consent form -\n\nExclusion Criteria:\n\nNone\n\n\\-","ALL","45 Years","70 Years",{"count":55,"type":56},6,"ESTIMATED","OBSERVATIONAL",[59],"Parkinson's Disease","NOT_YET_RECRUITING","2025-12-01",{"date":63,"type":64},"2025-12-12","ACTUAL",{"date":66,"type":56},"2025-12-15",{"date":68,"type":56},"2029-12-14",{"name":5,"class":6}]